Market Overview

UPDATE: Allergan Confirms Receipt of Unsolicited Proposal from Valeant, Will Review Offer

Share:
Related AGN
Here Are All The Big Biotech Mergers In 2016
Pfizer's $1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre-Split Prep?
Allergan and Adamas Pharma settle Namzaric patent fight with generic firm (Seeking Alpha)
Related VRX
Orexigen Shares Up 14% After Commercialization, Distribution Deal With Valeant Canada
Valeant Being Sued In NY Federal Court Over Alleged Overcharges
The Current Valuation Of Valeant Indicates At Least 50% Upside (Seeking Alpha)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals International, Inc. (“Valeant”) to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of the Company (the “Proposal”).

The Allergan Board of Directors, in consultation with its financial and legal advisors, will carefully review and consider the Proposal and pursue the course of action that it believes is in the best interests of the Company's stockholders. The Company's stockholders do not need to take any action at this time.

Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the Company and Latham & Watkins is serving as legal counsel to the Company.

Posted-In: News M&A Press Releases

 

Related Articles (AGN + VRX)

View Comments and Join the Discussion!